Vividion Therapeutics is a biopharmaceutical company founded in 2014 and headquartered in San Diego, CA. Vividion is a preclinical-stage biotech company focused on discovering small-molecule drugs that treat major unmet clinical needs using the first platform for proteome-wide ligand and target discovery. The company’s cutting-edge platform was spun out of the labs of Vividion’s scientific founders Ben Cravatt and Phil Baran, a team of highly innovative and very knowledgeable experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. Vividion is committed to advancing and applying its pioneering synthetic and proteomic chemistry platforms to create therapeutics that will make a transformative difference in patients.